Herbal seizures atypical symptoms after ibogaine intoxication: a case report
|
|
- Maximilian Richard
- 5 years ago
- Views:
Transcription
1 Breuer et al. Journal of Medical Case Reports (2015) 9:243 DOI /s CASE REPORT JOURNAL OF MEDICAL CASE REPORTS Open Access Herbal seizures atypical symptoms after ibogaine intoxication: a case report Lorenz Breuer 3,4, Burkhard S. Kasper 3,5, Bernd Schwarze 6, Juergen M. Gschossmann 7, Johannes Kornhuber 3 and Helge H. Müller 1,2* Abstract Introduction: Misuse of various new psychotropic substances such as ibogaine is increasing rapidly. Knowledge of their negative side effects is sparse. Case presentation: We present a case of intoxication with the herbal substance ibogaine in a 22-year-old white man. After taking a cumulative dose of 38 g (taken in two doses), he developed visual memories, nausea and vomiting. He developed a generalized tonic clonic seizure with additional grand mal seizures. He was treated with midazolam and levetiracetam. Extended drug screenings and computed tomography and magnetic resonance imaging findings were all negative. Conclusions: Knowledge of the side effects of ibogaine has mainly come from reports of cardiovascular complications; seizures are rarely mentioned and experimental findings are inconsistent. It seems that ibogaine acts like a proconvulsive drug at high doses. Keywords: Ibogaine misuse, Intoxication, Reactive seizures, Side effects Introduction The use of synthetic legal or semi-legal substances is increasing rapidly, especially in patients under the age of 30 years [1 4]. One such substance is ibogaine, a natural alkaloid extracted from the roots of the rain forest shrub Tabernanthe iboga. Ibogaine is known in alternative and rural medicine. In Gabon it is used for initiation ceremonies to induce a near-death experience for psychological purposes and to produce a rural-spiritual contact with the ancestors. It acts as a traditional high that includes hallucinations and feelings of depersonalization. In Western countries, the substance is used off-label and experimentally for the specific indication of detoxification from opiates, stimulants, alcohol and nicotine; in particular, it is used to treat withdrawal symptoms [5, 6]. Anticonvulsive and stimulant in vitro and in vivo effects were described for ibogaine [7]. The most commonly used form is the hydrochloride salt of ibogaine (HCl), * Correspondence: helge.mueller@karl-jaspers-klinik.de 1 Medical Campus University of OldenburgSchool of Medicine and Health Sciences Psychiatry and Psychotherapy, University Hospital Karl-Jaspers-Klinik, Hermann-Ehlers-Strasse 7 Bad Zwischenahn D-26160, Germany 2 Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany Full list of author information is available at the end of the article but alkaloid extracts or dried root bark are also used. Experimental findings suggested that ibogaine elevates plasma prolactin and corticosterone levels and that it is involved in decreasing dopamine (DA) neurotransmission. Ibogaine also decreases neurotransmission of serotonin receptors (5-hydroxytryptamine; 5-HT) in the striatum [7 11]. The anticonvulsive mode of action occurs via an N-methyl-d-aspartate (NMDA) receptor antagonism, a finding that has been well documented in experimental and therapeutic examinations [8, 12, 13]. The psychoactive state associated with ibogaine has been likened to a waking dream/dreamy state that sometimes includes interrogatory verbal exchanges. Another described experience is panoramic memory or the recall of rapid dense successions of autobiographical visual memories. These experiences have been associated with functional muscarinic cholinergic effects, which are prominent in the mechanisms of dreaming and memory [14, 15]. Ibogaine is used most frequently as a single oral dose in the range of 10 to 25 mg/kg of body weight. In the USA and most European countries, ibogaine is classified as an illegal drug [15, 16] Breuer et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
2 Breuer et al. Journal of Medical Case Reports (2015) 9:243 Case presentation We report the case of a 22-year-old white man in good physical health (body height of 184 cm; body weight of 76.6 kg) who used ibogaine for the first time; he had no history of acute or chronic illness and no history of any drug dependence. He had no concomitant use of prescribed medications. Prior to admittance he had not taken any somatic medication for approximately 6 months. According to his own statement, he wanted to achieve a spiritual cleansing and reboot by taking ibogaine. He had ordered dried ibogaine root bark via the Internet and took a cumulative dose of 38 g. He took two portions with <5 minute of latency between the two doses, grinding it and dissolving it in water. He reported having visions that occurred approximately 1 hour after he consumed the substance, which is a typical finding in ibogaine use [10, 11]. These visions, which mainly consisted of visual memories of his life, lasted for 10 minutes. Subsequently, he felt nauseated and had to vomit repeatedly. Over the next 30 minutes, the vomiting continued and he started to develop muscle tension and cramps in his arms and legs. Ten hours after he took the drug, his relatives found him having a generalized (tonic clonic) seizure (please see also Fig. 1). The emergency physician administered midazolam intravenously. The patient was immediately admitted to our intensive care unit, where he had several grand mal seizures. Within the next 3 days, repeated administrations of midazolam were necessary to stop the persistent generalized seizures. Anticonvulsive treatment with Page 2 of 5 levetiracetam (1000 mg) was initiated on day two and immediately stopped the symptoms He was constantly awake and had no further neurologic progression (for example tremor, clonus or hyperreflexia). Cranial computed tomography and magnetic resonance tomography did not show any pathological findings. All laboratory tests showed unspecific alterations which might be related to the multiple previous epileptic seizures. In addition, slightly increased C-reactive protein (CRP) values and white blood cell counts (including lymphocyte count and neutrophil count), mild decreased platelet counts and elevated creatine-kinase values were found temporarily during the first days after admission. No signs of an infection and no inflammatory process were found. His neurological status on day two revealed mild dysarthria with a subjective feeling of heaviness of the tongue, mild bilateral ptosis and psychomotor slowness. An electroencephalogram (EEG) showed mild diffuse encephalopathic changes but no epileptiform activity. On day five, all symptoms had disappeared completely and the laboratory values had normalized. Only the already declining creatine-kinase remained slightly increased, which was consistent with his several previous tonic clonic epileptic seizures. He was finally discharged from our hospital. During a 3month control period after this event that included documented abstinence, he had no further seizures without levetiracetam treatment, which had been tapered off after a few weeks. Detailed information about clinical and laboratory findings is provided in Table 1. Fig. 1 Electroencephalogram at day four after ibogaine intoxication. The electroencephalogram shows an irregular alpha rhythm and a significant portion of diffuse theta waves consistent with recent intoxication. No focal slowing and no epileptiform discharges are shown
3 Breuer et al. Journal of Medical Case Reports (2015) 9:243 Page 3 of 5 Table 1 Apparatus and laboratory findings during the observation period after ibogaine intoxication Type of analysis Day 1 Day 2 Day 3 Day 4 Day 5 Computed tomography No pathological findings Magnetic resonance imaging Electrocardiogram No pathological findings Sinus tachycardia (>120 beats per minute)/sinus rhythm Sinus rhythm Sinus rhythm 55 beats per minute; QTc: 100 % Month 3 Electroencephalogram Irregular alpha rhythm, significant portion of diffuse theta waves, no focal slowing, no epileptiform discharges Regular alpha rhythm, no focal slowing, no epileptiform discharges Laboratory findings Reference values White blood cell count ( 10 3 /μl) Platelet count ( 10 3 /μl) Lymphocyte count (%) Neutrophil count (%) Creatinine (mg/dl) <1.2 Creatine-kinase (U/l) <190 C-reactive protein (mg/l) Carbohydrate-deficient 1.59 <2.6 transferrin (%) Ibogaine concentration 22 in hair sample (pg/mg) Noribogaine concentration in hair sample (pg/mg) 70 Noribogaine concentration in urine sample (ng/mg) 9.2 Pathological findings are marked in bold. All other routine parameters (for example liver enzymes, electrolytes, coagulation status, triglycerides, cholesterol, thyroid-stimulating hormone, free triiodothyronine, and free thyroxine), as well as the screening for drugs in the patient s urine (benzodiazepine, amphetamine, morphine/opiate/heroin, barbiturates, ecstasy/3,4-methylenedioxy-methamphetamine, methadone, cocaine metabolites, methamphetamine, tetrahydrocannabinol, fentanyl, tricyclic antidepressants, buprenorphine), and in the serum (barbiturates, benzodiazepine, tricyclic antidepressants) showed no pathological findings Discussion Knowledge about the potential side effects of ibogaine is sparse. Sudden deaths have been related to the use of ibogaine, mainly because of concomitant medication use and comorbidities (especially cardiovascular) and/or its use among drug users as a self-treatment for detoxification. Most reports have noted fatal cardiac symptoms with QT prolongation and cardiac arrhythmias [17, 18]. By contrast, our patient survived without any detected severe electrocardiogram (ECG) abnormalities. Alper et al. reported the case of a patient who presented observed and well-documented seizures directly related to ibogaine, which the patient did not take for detoxification purposes [19]. In addition to the known psychotropic effects, our patient showed additional reactive generalized epileptic seizures caused by ibogaine. He had no additional history of drug abuse, so a substance-induced trigger could be excluded. Also an interaction of ibogaine with prescribed substances as a potentiator of the seizure events could be excluded in this case. This description of a seizure induction via ibogaine misuse is rare and is in contrast to the supposed anticonvulsive mode of action via NMDA receptor antagonism of ibogaine which seems to mediate the anticonvulsive effects of the substance [20, 21]. In clinical settings a paradoxical seizure exacerbation by anti-epileptic medication is a known clinical phenomenon but the cellular mechanisms still remain unclear [22, 23]. One possible explanation might be an enhanced disinhibition process by a dose-dependent suppression of inhibitory interneurons. Ibogaine like
4 Breuer et al. Journal of Medical Case Reports (2015) 9:243 Page 4 of 5 MK-801 (dizocilpine) also stimulates a release of glucocorticoids that in turn increase susceptibility to seizures. The seizures observed in our patient could be related to the same glucocorticoid effect [8]. Binienda et al. described that MK-801 (dizocilpine) which also acts as an NMDA antagonist, paradoxically enhances electrographic seizures that preceded suppression of status epilepticus [24]. Although we cannot provide the exact ibogaine concentration of the dried root bark that our patient used, a dose of 38 g is high compared with the doses of 2 to 30 g of dried ibogaine root bark reported in literature [25]. Assuming an ibogaine concentration of 7 %, as previously reported [26], this would have corresponded to a single ingestion dosage of 2260 mg, or 35 mg/kg. It can be assumed that in our patient s case, ibogaine acted like a high-dose-dependent proconvulsive drug while in lower doses being generally supposed to have an anticonvulsive mode of action. This finding could stimulate further experimental studies to examine this hypothesis of a dose-dependent convulsive mode of action of ibogaine. Conclusions It seems that in addition to its psychotropic and cardiac risk profile, ibogaine also has a substantial proconvulsive mode of action that is atypical given its NMDA antagonism, and this is potentially dose dependent. Of course, the significance of this finding is limited because only one documented case exists. Nevertheless, more case examinations and experimental findings could probably prove this hypothesis of a dose-dependent proconvulsive mode of action of ibogaine in higher consumed doses. These upcoming examinations should integrate and control for experimental findings that postulate that ibogaine has anticonvulsive effects [7]. Overall, taking into account the rising consumption of extraordinary herbal substances and the increasing number of reported side effects, physicians should be aware of this clinical manifestation of ibogaine use. Consent Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare that they have no competing interests. Authors contributions The authors alone are responsible for writing the manuscript. LM, JMG, HHM, and BSK were responsible for treating the patient. LB and HHM wrote the manuscript. BS performed the forensic and laboratory analytics and quality control measures. BSK critically revised the manuscript and gave expert opinion on seizure treatment. JK critically revised the manuscript and gave expert opinion on ibogaine and its mode of action as a NMDA receptor antagonist. JMG and HHM critically revised the manuscript and gave expert opinion on intensive care and drug abuse treatment. All authors approved the final manuscript. Acknowledgements We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) within the funding program Open Access Publishing. Author details 1 Medical Campus University of OldenburgSchool of Medicine and Health Sciences Psychiatry and Psychotherapy, University Hospital Karl-Jaspers-Klinik, Hermann-Ehlers-Strasse 7 Bad Zwischenahn D-26160, Germany. 2 Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany. 3 Department of Neurology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany. 4 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany. 5 Epilepsy Center, Department of Neurology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany. 6 Department of Forensic Medicine, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. 7 Department of Internal Medicine, Klinikum Forchheim/Friedrich-Alexander Universität Erlangen-Nuremberg, Erlangen, Germany. Received: 5 May 2015 Accepted: 8 October 2015 References 1. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32: Muller H, Huttner HB, Kohrmann M, Wielopolski JE, Kornhuber J, Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry. 2010;43: Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010;118: Cabriales JA, Cooper TV, Taylor T. Prescription drug misuse, illicit drug use, and their potential risk and protective correlates in a Hispanic college student sample. Exp Clin Psychopharmacol. 2013;21: Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6: Gevirtz C. Anesthesia for opiate detoxification and the ibogaine controversy. Int Anesthesiol Clin. 2011;49: Leal MB, de Souza DO, Elisabetsky E. Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochem Res. 2000;25: Ali SF, Newport GD, Slikker Jr W, Rothman RB, Baumann MH. Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation. Brain Res. 1996;737: Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, et al. Effect of Iboga alkaloids on micro-opioid receptor-coupled G protein activation. PLoS One. 2013;8, e Popik P, Layer RT, Fossom LH, Benveniste M, Geter-Douglass B, Witkin JM, et al. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J Pharmacol Exp Ther. 1995;275: Popik P, Wrobel M. Anxiogenic action of ibogaine. Alkaloids Chem Biol. 2001;56: Wasterlain CG, Naylor DE, Liu H, Niquet J, Baldwin R. Trafficking of NMDA receptors during status epilepticus: therapeutic implications. Epilepsia. 2013;54 Suppl 6: Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43: Cantero JL, Atienza M, Stickgold R, Kahana MJ, Madsen JR, Kocsis B. Sleepdependent theta oscillations in the human hippocampus and neocortex. J Neurosci. 2003;23: Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 2012;35:
5 Breuer et al. Journal of Medical Case Reports (2015) 9:243 Page 5 of Galea S, Lorusso M, Newcombe D, Walters C, Williman J, Wheeler A. Ibogaine be informed before you promote or prescribe. J Prim Health Care. 2011;3: Alper KR. Ibogaine: a review. Alkaloids Chem Biol. 2001;56: Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360: Alper KR, Stajic M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57: Dhir A, Chopra K. Memantine delayed N-Methyl-D-Aspartate (NMDA)- induced convulsions in neonatal rats. Fundam Clin Pharmacol. 2014;29(1): Xu H, Ou F, Wang P, Naren M, Tu D, Zheng R. High dosage of agmatine alleviates pentylenetetrazole-induced chronic seizures in rats possibly by exerting an anticonvulsive effect. Exp Ther Med. 2014;8: Rheims S, Ryvlin P. Pharmacotherapy for tonic-clonic seizures. Expert Opin Pharmacother. 2014;15: Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol doi: /bcp [Epub ahead of print]. 24. Binienda ZK, Scallet AC, Schmued LC, Ali SF. Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods. Alkaloids Chem Biol. 2001;56: Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115: Mazoyer C, Carlier J, Boucher A, Peoc h M, Lemeur C, Gaillard Y. Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. J Forensic Sci. 2013;58: Submit your next manuscript to BioMed Central and take full advantage of: Convenient online submission Thorough peer review No space constraints or color figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which is freely available for redistribution Submit your manuscript at
Cardiac arrest after ibogaine intoxication
1 of 6 10/28/2018 8:18 PM J Arrhythm. 2018 Aug; 34(4): 455 457. Published online 2018 Jun 12. doi: [10.1002/joa3.12061] PMCID: PMC6111465 PMID: 30167018 Cardiac arrest after ibogaine intoxication Christian
More informationIbogaine-associated cardiac arrest and death: case report and review of the literature
1 of 6 11/29/2018 12:27 PM Ther Adv Psychopharmacol. 2016 Apr; 6(2): 95 98. Published online 2016 Jan 13. doi: [10.1177/2045125315626073] PMCID: PMC4837967 PMID: 27141291 Ibogaine-associated cardiac arrest
More informationA substance that reduces pain and may or may not have psychoactive properties.
GLOSSARY OF TERMS AMPHETAMINE-TYPE STIMULANTS (ATS) A group of substances, mostly synthetic, with closely related chemical structure which have, to varying degrees, a stimulating effect on the central
More informationNew Drugs of Abuse. Three Parts to US Federal Analog Act. Federal Analog Act (1986)
New Drugs of Abuse Hannah Hays, MD Assistant Professor Practice Department of Emergency Medicine Department of Pediatrics Nationwide Children s Hospital The Ohio State University Wexner Medical Center
More informationPlease review the following slides prior to class. Information from these slides will be used to answer patient cases. Come prepared!
Please review the following slides prior to class Information from these slides will be used to answer patient cases. Come prepared! Alcohol and Opiate Dependence Reference Slides Substances of Abuse A
More informationEffective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)
1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory
More informationTianeptine Dependence: A Case Report
CASE REPORT Tianeptine Dependence: A Case Report Syed Nabil, Ng Chong Guan, Rusdi Abd Rashid Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia Abstract
More informationMethamphetamine Abuse During Pregnancy
Methamphetamine Abuse During Pregnancy Robert Davis, MD / r.w.davismd@gmail.com ❶ Statistics ❷ Pregnancy Concerns ❸ Postpartum Concerns ❹ Basic Science ❺ Best Practice Guidelines ❻ Withdrawal ❼ Recovery
More informationWhat is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration
What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,
More informationA. Incorrect! Seizures are not typically linked to alcohol use. B. Incorrect! Epilepsy is a seizure that is commonly associated with convulsions.
Pharmacology - Problem Drill 17: Central Nervous System Depressants Question No. 1 of 10 Instructions: (1) Read the problem statement and answer choices carefully (2) Work the problems on paper as 1. occur(s)
More informationControlled Substance Monitoring and Drugs of Abuse Testing Determination
CPT s: 80305 Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (eg, immunoassay); capable of being read by direct optical observation only (eg, dipsticks, cups,
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationSubstances under Surveillance
Substances under Surveillance The following substances are under surveillance by the World Health Organization (WHO) as they are considered to have the potential to cause public health harm. For ease of
More informationdistinguish between structural isomers (but not necessarily stereoisomers), including, but not
CPT s: 80305 Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (eg, immunoassay); capable of being read by direct optical observation only (eg, dipsticks, cups,
More information*Pathophysiology of. Epilepsy
*Pathophysiology of Epilepsy *Objectives * At the end of this lecture the students should be able to:- 1.Define Epilepsy 2.Etio-pathology of Epilepsy 3.Types of Epilepsy 4.Role of Genetic in Epilepsy 5.Clinical
More informationSubstance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %
Substance Use Disorders A Major Problem Lifetime rates of alcoholism estimated at 13.4 % Rates of drug abuse estimated at 6% Marijuana is most frequent Approximately 600,000 deaths each year from substance
More informationMale Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: gmail.
RESEARCH ARTICLE Open Access Male Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: drsujita@gmail.com; saranya296@ gmail.com Full list of author information
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Clinical Case Challenge: Seizure Emergency
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationMOLECULAR BIOLOGY OF DRUG ADDICTION. Sylvane Desrivières, SGDP Centre
1 MOLECULAR BIOLOGY OF DRUG ADDICTION Sylvane Desrivières, SGDP Centre Reward 2 Humans, as well as other organisms engage in behaviours that are rewarding The pleasurable feelings provide positive reinforcement
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationThe causes of misuse:
The Drug Misuse The causes of misuse: Availability of drugs. A vulnerable personality. Adverse social environment. Regular drug taking play a role. Determining misuse and dependence, it is unclear whether
More informationMEDICARE LOCAL COVERAGE DETERMINATION COMMONLY USED DIAGNOSIS CODES
MEDICARE LOCAL COVERAGE DETERMINATION COMMONLY USED DIAGNOSIS CODES Urine drug testing (UDT) provides objective information to assist clinicians in identifying the presence or absence of drugs or drug
More informationPolysubstance Use & Medication-Assisted Treatment
Polysubstance Use & Medication-Assisted Treatment DSM-V eliminated polysubstance disorder, instead specifying each drug of abuse and dependence. Substance-use disorder is a combination of the two DSM-IV
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationAP Psychology. Objective 1: Videos & Synopses. Video 1 type a detailed video 1 synopsis: (Type your response here)
AP Psychology Directions: Complete each of the objectives below using the States of Consciousness Flipped Unit document. Please type all of your responses do not just copy and paste definitions. Instead,
More informationAn Introduction to Forensic Toxicology
An Introduction to Forensic Toxicology Jennifer Shea, PhD, FCACB Ken Obenson, MBBS MFFLM (UK) FRCPC (Anat) FRCPC (Forensic Path) Dip American Brd of Path (Anat & Clin/Cytopath/Forensic Path) April 11,
More informationSeizures. What is a seizure? How does it occur?
Seizures What is a seizure? A seizure is a symptom, not a disease. It happens when nerve cells in the brain function abnormally and there is a sudden abnormal electrical signal in the brain. The seizure
More informationDrugs and the Brain. Sooren Moosavy and Vanessa Travieso
Drugs and the Brain Sooren Moosavy and Vanessa Travieso What are drugs? DRUG: any substance which, when ingested in relatively small amounts, induces a physiological change LD50 lethal dose 50% = dose
More informationConventional and emerging drugs of abuse: the current situation
Conventional and emerging drugs of abuse: the current situation NEW PSYCHOACTIVE SUBSTANCES -THE HIGHS AND LOWS Maritim Hotel, Munich, 12-13 November 2015 Michael Uhl Director of Chemistry Unit Bavarian
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationPeripheral neuropathy (PN)
Peripheral neuropathy (PN) damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic:
More informationNeuropathophysiologyof
Neuropathophysiologyof Epilepsy and Psychiatric Comorbidity & Diagnosis and Management of Non- Epileptic Attack Disorders N Child Neurologist Auckland City Hospital Psychiatric Disorders associated with
More informationAddiction. Julia E. Linton York College/ Wellspan Health Nurse Anesthesia Program
Addiction Julia E. Linton York College/ Wellspan Health Nurse Anesthesia Program Objectives Identify patient populations at risk for drug abuse Identify several common drugs of abuse and the MOA Identify
More informationSubstance Use Disorders
Substance Use Disorders Substance Use Disorder This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationPATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone
PATIENT INTAKE: MEDICAL HISTORY Name Address Phone (W) (H) (C) DOB Age SS# Emergency Contact Relationship to patient Phone Primary care physician Phone Have you ever had an EKG? Y N Date Current or past
More informationThe future of pharmacological treatment.
The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017 Disclosures One
More informationsensory nerves, motor nerves, autonomic nerves
damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic: long term, begins subtly
More informationHow long does.5 mg xanax stay in your system
Search Search How long does.5 mg xanax stay in your system Xanax half life: how long does Xanax stay in your system.. Xanax half life: how long does Xanax now I m recommending Xanax. 5 mg to help her relax.
More informationUnit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders
Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders - Terminologies: Anti-convulsants: they are used to control convulsions seen in certain types of epilepsy. Convulsions may
More informationThe new psychoactive substances: Toxicity and management
The new psychoactive substances: Toxicity and management Bruno Mégarbane, MD, PhD Department of Medical and Toxicological Critical Care INSERM UMRS 1144 - Paris-Diderot University Lariboisière Hospital,
More informationIntroduction. 1 person in 20 will have an epileptic seizure at some time in their life
Introduction 1 person in 20 will have an epileptic seizure at some time in their life Epilepsy is diagnosed on the basis of two or more epileptic seizures. Around 450,000 people in the UK have epilepsy
More informationBenzodiazepines: risks, benefits or dependence
Benzodiazepines: risks, benefits or dependence A re-evaluation Council Report CR 59 January 1997 Royal College of Psychiatrists, London Due for review: January 2002 1 Contents A College Statement 3 Benefits
More informationNew Zealand Ibogaine treatment outcomes for opioid dependence: Another string to the bow?
New Zealand Ibogaine treatment outcomes for opioid dependence: Another string to the bow? Geoff Noller, PhD; Chris Frampton, PhD; Berra Yazar-Klosinski, PhD Addiction Research Symposium, Christchurch,
More informationThe updated incidences and mortalities of major cancers in China, 2011
DOI 10.1186/s40880-015-0042-6 REVIEW Open Access The updated incidences and mortalities of major cancers in China, 2011 Wanqing Chen *, Rongshou Zheng, Hongmei Zeng and Siwei Zhang Abstract Introduction:
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More informationGlencoe Health. Lesson 3 Psychoactive Drugs
Glencoe Health Lesson 3 Psychoactive Drugs Health espotlight Video BIG IDEA Psychoactive drugs affect the central nervous system and can be especially damaging to the developing brain and body of a teen.
More informationElectroencephalography. Role of EEG in NCSE. Continuous EEG in ICU 25/05/59. EEG pattern in status epilepticus
EEG: ICU monitoring & 2 interesting cases Electroencephalography Techniques Paper EEG digital video electroencephalography Dr. Pasiri Sithinamsuwan PMK Hospital Routine EEG long term monitoring Continuous
More informationNEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE
NEONATAL ABSTINENCE SYNDROME (NAS) AKA NEWBORN DRUG WITHDRAWAL:THE NEWARK EXPERIENCE Salma Ali MD, Debra Brendel RN, BSN, MSN and Ona Fofah MD Division of Neonatology and Newborn Medicine Department of
More informationSpice: A New Legal Herbal Mixture Abused by Young Active Duty Military Personnel
Substance Abuse, 33:191 194, 2012 Copyright c Taylor & Francis Group, LLC ISSN: 0889-7077 print / 1547-0164 online DOI: 10.1080/08897077.2011.637610 Spice: A New Legal Herbal Mixture Abused by Young Active
More informationMEDICAL POLICY Drug Testing
POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 11/13/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Anesthetics for the Treatment of Chronic Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravenous_anesthetics_for_the_treatment_of_chronic_pain
More informationSynthetic cannabinoids: Flying high under the RADAR Brett Ginsburg, Ph.D.
Synthetic cannabinoids: Flying high under the RADAR Brett Ginsburg, Ph.D. Introduction Brett Ginsburg, Ph.D. Associate Professor Department of Psychiatry Introduction What are synthetic cannabinoids? Manufacture
More informationLearning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly
Utilization of the urine drug screen: The good, the bad, and the ugly Jennifer A. Lowry, MD Chief, Section of Medical Toxicology Children s Mercy Hospital Kansas City, MO Learning Objectives Describe the
More informationCHD 110 PSYCHOPHARMACOLOGY AND SUBSTANCE ABUSE
CHD 110 PSYCHOPHARMACOLOGY AND SUBSTANCE ABUSE PRESENTED AND APPROVED: DECEMBER 7, 2012 EFFECTIVE: FALL 2013-14 Prefix & Number CHD 110 Purpose of this submission: Change course title to reflect current
More informationA handful of dangerous new legal drugs has public health experts worried
Page 1 of 8 A handful of dangerous new legal drugs has public health experts worried MATTHEW SPEISER AUG. 11, 2015, 5:00 PM Over the past 20 years, the drug world has seen the rise of new psychoactive
More informationPharming, the new way to party. Presented by: Carrie Terrill, LCDC
Pharming, the new way to party Presented by: Carrie Terrill, LCDC The contents of your medicine cabinet may seem harmless, but have the potential to be dangerous, addictive, and even deadly. What is Pharming
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationTreatment of opioid use disorder with ibogaine: detoxification and drug use outcomes
The American Journal of Drug and Alcohol Abuse Encompassing All Addictive Disorders ISSN: 0095-2990 (Print) 1097-9891 (Online) Journal homepage: http://www.tandfonline.com/loi/iada20 Treatment of opioid
More informationBAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH
BAPTIST HEALTH SCHOOL OF NURSING NSG 3036A: PSYCHIATRIC-MENTAL HEALTH THERAPEUTIC INTERVENTION AND RESOURCE MANAGEMENT: SUBSTANCE RELATED DISORDERS: CO-DEPENDENCY AND THE IMPAIRED NURSE LECTURE OBJECTIVES:
More informationSuccessful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report
*Manuscript Click here to view linked References Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report Thompson AGB 1, Cock HR 1,2. 1 St George s University
More informationCell body, axon, dendrite, synapse
SOME BASIC NEUROSCIENCE Neurons have specialised extensions 1: Label the parts of a neuron by selecting the correct term from the box below. Cell body, axon, dendrite, synapse 1 dendrite synapse cell body
More information8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis
8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis Ruby S. Grewal, MD and Tony P. George, MD, FRCPC As cannabis consumption rises, there has been significant emerging evidence
More informationEvaluating an Apparent Unprovoked First Seizure in Adults
Evaluating an Apparent Unprovoked First Seizure in Adults Case Presentation A 52 year old woman is brought to the emergency room after a witnessed seizure. She was shopping at the local mall when she was
More informationThe efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study
Tiamkao et al. BMC Neurology 2013, 13:98 RESEARCH ARTICLE Open Access The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study Somsak
More informationPsychoactive Drugs. Psychoactive drug: A chemical substance that alters perceptions and mood.
LP 5C Drugs and alcohol 1 Psychoactive Drugs Psychoactive drug: A chemical substance that alters perceptions and mood. Your textbook characterizes three broad categories of psychoactive drugs Depressants:
More informationDoes ultram show up as an opiate
Search Does ultram show up as an opiate Tramadol ( Ultram ) is prescribed for treating moderate to severe pain in adults. 19-2-2018 I took Tramadol Hydrochloride for 6 months due to joint pain from my
More informationCannabis for Medical Use: Body and Mind
Cannabis for Medical Use: Body and Mind Shaul Schreiber, MD Division of Psychiatry, Tel Aviv Sourasky Medical Center; Tel Aviv University Sackler Faculty of Medicine; Sagol School of Neuroscience, Israel
More informationSeizure-Triggered Vagus Nerve Stimulation Using Patient-Specific Seizure Onset Detection
Seizure-Triggered Vagus Nerve Stimulation Using Patient-Specific Seizure Onset Detection Ali Shoeb, Alaa Kharbouch, John Guttag Massachusetts Institute of Technology, Cambridge, MA, USA Trudy Pang, Steven
More information3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD
Psychopharmacology at the End of Life Nicole Thurston, MD Psychiatrist Mountain States Tumor Institute Objectives Describe 2 common psychiatric symptoms that can present at or near end of life. Review
More informationOverview of the AACC Academy s LMPG: Using clinical laboratory tests to monitor drug therapy in pain management patients
Overview of the AACC Academy s LMPG: Using clinical laboratory tests to monitor drug therapy in pain management patients Gwen McMillin, PhD, DABCC(CC,TC) Professor, University of Utah Medical Director,
More informationEMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING AUTHORISATION FOR ORLAAM (LEVACETYLMETHADOL) IN THE EUROPEAN UNION
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 19 April 2001 EMEA/8776/01 EMEA PUBLIC STATEMENT ON THE RECOMMENDATION TO SUSPEND THE MARKETING
More informationEpilepsy CASE 1 Localization Differential Diagnosis
2 Epilepsy CASE 1 A 32-year-old man was observed to suddenly become unresponsive followed by four episodes of generalized tonic-clonic convulsions of the upper and lower extremities while at work. Each
More informationCONSCIOUSNESS AND THE TWO-TRACK MIND
Chapter 3 CONSCIOUSNESS AND THE TWO-TRACK MIND Forms of Consciousness Modern psychologists believe that consciousness is an awareness of ourselves and our environment. Consciousness is not whether or not
More informationMEDICAL POLICY Drug Testing
POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 04/10/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each
More informationCases of Patients with OUD. Objectives
Cases of Patients with OUD Soraya Azari, MD Objectives To dive further into cases of patients related to OUD, including some more challenging cases from the inpatient setting. To refine your skills at
More informationRefractory Status Epilepticus in Children: What are the Options?
Refractory Status Epilepticus in Children: What are the Options? Weng Man Lam, PharmD, BCPS, BCPPS PICU Clinical Pharmacy Specialist Memorial Hermann Texas Medical Center November 11, 2017 Objectives 1.
More information201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.
201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. RELATES TO: KRS 311.530-311.620, 311.990 STATUTORY AUTHORITY: KRS
More informationTHEXANAX THREAT 1 THE XANAX THREAT. iaddiction.com
THEXANAX THREAT 1 THE XANAX THREAT 3 6 9 11 SOCIETAL IMPACT OF XANAX RECREATIONAL VALUE OF XANAX THE PHYSICAL, MENTAL, AND EMOTIONAL EFFECTS OF XANAX ADDICTION AND DEPENDENCE Societal Impact of Xanax Since
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationOutcomes of Infants with Neonatal Abstinence Syndrome
Outcomes of Infants with Neonatal Abstinence Syndrome Caroline O. Chua, MD, FAAP Medical Director, Division of Neonatology Director, Neonatal Follow Up Clinic Nemours Children s Hospital Orlando, Florida
More informationCutoff levels for hydrocodone in a blood test
Cutoff levels for hydrocodone in a blood test The premier DNA and drug testing company in the North Texas area. Specializing in legal cases but also provide testing for employers and private individuals.
More informationSubstance Abuse in US and Europe
Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health Professor, University of Colorado School of Medicine Supply of Legal Opioid Analgesics
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,
More informationNovel Psychoactive Substances. Legal Highs. Dr James Dear
Novel Psychoactive Substances Legal Highs Dr James Dear Consultant Toxicologist NPIS Edinburgh What am I going to cover? National Poisons Information Service Novel Psychoactive Substances History, classification,
More informationObjectives. Amanda Diamond, MD
Amanda Diamond, MD Objectives Recognize symptoms suggestive of seizure and what those clinical symptoms represent Understand classification of epilepsy and why this is important Identify the appropriate
More informationMEDICAL POLICY No R2 DRUG TESTING
Summary of Changes MEDICAL POLICY DRUG TESTING Effective Date: April 10, 2017 Review Dates: 5/15, 5/16, 11/16, 2/17 Date Of Origin: May 13, 2015 Status: Current Clarifications: Deletions: Additions: Pg.
More informationFOLLOW DIRECTIONS. How to Use Methadone Safely. U.S. Department of Health & Human Services
FOLLOW DIRECTIONS How to Use Methadone Safely U.S. Department of Health & Human Services Substance Abuse and Mental Health Services Administration Food and Drug Administration Methadone Methadone provides
More informationReporting a Case of Injecting Methylphenidate (Ritalin) Tablets, Intensified Symptoms of Schizoph-renia or Induce Separate Mental Disorder?
Case Report Addiction and Health Vol 1, No 2, Fall 2009 Received: 6.10.2009 Accepted:17.11.2009 Background: Case Report: Conclusion: Key words: Page count: Tables: Figures: References: Address of Correspondence:
More informationA CHRONOLOGY OF SELECTED ABSTRACTS IBOGAINE:
A CHRONOLOGY OF SELECTED ABSTRACTS IBOGAINE: Rapid Method for the Interruption of the Narcotic Addiction Syndrome Presented as a Courtesy to the American Association for the Treatment Opioid Dependence
More informationAlcohol withdrawal. Clinical features
Alcohol withdrawal Clinical features Severity increase with amount consumed; uncommon with < drinks per day. Predictable pattern: patients with previous withdrawal seizures are at high risk for recurrence.
More informationMedication Guide Fluoxetine Oral Solution USP What is the most important information I should know about fluoxetine oral solution?
Medication Guide Fluoxetine Oral Solution USP Read the Medication Guide that comes with fluoxetine before you start taking it and each time you get a refill. There may be new information. This Medication
More informationProposed Revision to Med (i)
Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationStates of Consciousness
Myers PSYCHOLOGY (7th Ed) Chapter 7 States of Consciousness Waking Consciousness Consciousness our awareness of ourselves and our environments Sleep and Dreams Biological Rhythms periodic physiological
More informationTHE SYNTHETIC DRUGS. Timothy E. Wilens, MD
THE SYNTHETIC DRUGS Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical School Disclosures*
More informationEU RISK MANAGEMENT PLAN (EU-RMP)
EU RISK MANAGEMENT PLAN (EU-RMP) HYDROXYZINE 25 mg, scored film-coated tablets Active substance(s) (INN or common name): Hydroxyzine hydrochloride Pharmaco-therapeutic group (ATC Code): N05BB01, Anxiolytics
More information